Floatz logo

Tildacerfont

21-OHD

Spruce BiosciencesSmall moleculePhase 2Active
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
23/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the 21-OHD cohort.

Asset / SponsorPhaseRating
Solu-Cortef
Neurocrine UK Limited
Phase 1/2NR

Same molecule, other indications

Tildacerfont is also rated in:

congenital adrenal hyperplasiaDormant
CC
Indicative ·
41 / 100
View asset →
classic congenital adrenal hyperplasiaDormant
CC
Indicative ·
41 / 100
View asset →
polycystic ovary syndromeDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →